A Study of Subcutaneous Mircera for the Treatment of Anemia in Pre-Dialysis Participants With Chronic Kidney Disease.
Status:
Terminated
Trial end date:
2011-04-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy and safety of subcutaneous Mircera for
correction of anemia in participants with chronic kidney disease who are not on dialysis and
are not treated with erythropoiesis-stimulating agents (ESA). Eligible participants will
receive Mircera by monthly subcutaneous injections, dependent on body weight (with a starting
dose of 1.2 micrograms/kilogram [mcg/kg]). The anticipated time on study treatment is 3-12
months, and the target sample size is 100-500 individuals.